Vaccines

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

A breakthrough oral vaccine from Singaporean scientists promises to end a devastating fish virus, bolstering food security and transforming aquaculture economics.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

Despite passing all resolutions, Novavax faces a reckoning as nearly half of shareholders reject its pay plan, amplifying activist investor Shah Capital's demands.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

The Senate's new Naloxone Awareness Day highlights a critical shift. As fentanyl rages, a life-saving drug is moving from ambulances to school hallways.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.